SB 2370: AN ACT to provide for a legislative management study regarding prescription drug transparency reporting under the federal drug discount program.
SB 2370 status: Introduced — Filed with Secretary Of State 05/02 (updated Jun 11, 2025).
What this bill does
Overall score
Bill summary
OfficialThis bill asks lawmakers to study how we track the prices of prescription drugs in government discount programs to make sure the system is working properly. The Senate is currently deciding whether to approve this study.
Key analysis
Impact analysis
Environment
Benefits
- No direct sector effect identified.
Risks
- No direct sector effect identified.
Economy
Benefits
- Potential for identifying cost-saving measures in drug procurement.
- Increased transparency in government drug discount programs.
Risks
- Costs associated with administrative study time and reporting.
- Outcome of the study remains speculative.
Society
Benefits
- Aligns with public interest in prescription drug affordability.
- Strengthens oversight of taxpayer-funded health programs.
Risks
- Study results do not guarantee legislative action or lower drug costs.
How trustworthy & consequential it is
Source
OpenStates
Confidence
lowlow
Analysis status
OpenStates summary
Legislative studies are non-binding and do not mandate changes in law.
Analysis based on limited summary abstract only.
Where it stands
Introduced
CurrentFiled with Secretary Of State 05/02
Committee
UpcomingFloor
UpcomingGovernor
UpcomingEnacted
UpcomingHow it affects your district
Set your location
Add your district to see how this bill may affect your community and who to contact.
Take action
Contact your representatives
Let them know how you feel about this bill.
Share your view
Join the discussion and see what others are saying.
Track this bill
Stay updated on progress and changes.